1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. California >
  6. Allergan Acquires ForSight VISION5

M&A Deal Summary

Allergan Acquires ForSight VISION5

On August 11, 2016, Allergan acquired medical products company ForSight VISION5 from ForSight Labs for 95M USD

Acquisition Highlights
  • This is Allergan’s 7th transaction in the Medical Products sector.
  • This is Allergan’s 18th largest (disclosed) transaction.
  • This is Allergan’s 17th transaction in the United States.
  • This is Allergan’s 5th transaction in California.

M&A Deal Summary
Date 2016-08-11
Target ForSight VISION5
Sector Medical Products
Buyer(s) Allergan
Sellers(s) ForSight Labs
Deal Type Divestiture
Deal Value 95M USD

Target

ForSight VISION5

Menlo Park, California, United States
ForSight VISION5, Inc. is a developer of non-invasive drug delivery products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy.

Search 205,859 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Allergan

Parsippany, New Jersey, United States
Category Company
Founded 1956
Sector Life Science
Employees31,200
Revenue 15.8B USD (2018)
DESCRIPTION

Allergan is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.

DEAL STATS #
Overall 26 of 38
Sector (Medical Products) 7 of 11
Type (Divestiture) 6 of 7
State (California) 5 of 9
Country (United States) 17 of 27
Year (2016) 3 of 9
Size (of disclosed) 18 of 25
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-02 Anda

Parsippany, New Jersey, United States

Anda, Inc. is a distributor of generic pharmaceuticals.

Sell $500M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-09-06 RetroSense Therapeutics

Ann Arbor, Michigan, United States

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. There are currently no FDA-approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The Company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. RetroSense has worldwide exclusive rights to the relevant intellectual property from both institutions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic.

Buy $60M

Seller(S) 1

SELLER

ForSight Labs

Menlo Park, California, United States
Category Company
Founded 2005
Sector Medical Products
DESCRIPTION

ForSight Labs LLC is an ophthalmic incubator provides medical products in US.

DEAL STATS #
Overall 3 of 4
Sector (Medical Products) 3 of 3
Type (Divestiture) 2 of 3
State (California) 3 of 4
Country (United States) 3 of 4
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-10-09 ForSight Newco II

Menlo Park, California, United States

ForSight Newco II, Inc. is a manufacture of medical products in US.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-10 ForSight VISION4

Menlo Park, California, United States

ForSight VISION4, Inc. is a privately held biotechnology company revolutionizing drug delivery for treatment of retinal diseases.

Sell -
Mergr

Product

Company

Legal